The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS)

Journal of Intellectual and Developmental Disability

Volumn 33, Issue 4, 2008, Pages 337-344

  Matson, Johnny L ^a   Fodstad, Jill C ^a   Rivet, Tessa T ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

DISCUS; Intellectual disabilities; MEDS; Psychotropics; Side effects; Validity

Indexed keywords

PSYCHOTROPIC AGENT;

ADULT; AGED; AKATHISIA; ARTICLE; BEHAVIOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DYSTONIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; SCORING SYSTEM; TARDIVE DYSKINESIA; TREMOR; VALIDITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MENTAL RETARDATION; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOMETRICS; PSYCHOTROPIC DRUGS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SOUTHEASTERN UNITED STATES; TIME FACTORS; YOUNG ADULT;

EID: 57049091656     PISSN: 13668250     EISSN: 14699532     Source Type: Journal    
DOI: 10.1080/13668250802478799     Document Type: Article

References (28)

1. Advokat, C. D., Mayville, E. A., & Matson, J. L. (2000). Side-effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with intellectual disability. Research in Developmental Disabilities, 21, 75-84.
2. American Psychiatric Association (APA). (2000). Diagnostic and Statistical Manual of Mental Disorders (4th ed.) - Text Revision. Washington, DC: APA.
3. Borison, R. L. (1995). Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. Journal of Clinical Psychopharmacology, 15(Suppl. 1), 24S-29S.
4. Campbell, D. T., & Fiske, D. W. (1959). Convergent and discriminant validation by the multitrait-multimethod matrix. Psychological Bulletin, 56, 81-105.
5. Campbell, M., Young, P. I., Bateman, D. N., Smith, J. M., & Thomas, S. H. L. (1999). The use of atypical antipsychotics in the management of schizophrenia. British Journal of Clinical Pharmacology, 47(1), 13-22.
6. Fox, R. A., Keller, K. M., Grede, P. L., & Bartosz, A. M. (2007). A mental health clinic for toddlers with developmental delays and behavior problems. Research in Developmental Disabilities, 28, 119-129.
7. Hove, O. (2007). Survey on dysfunctional eating behavior in adult persons with intellectual disability living in the community. Research in Developmental Disabilities, 28, 1-8.
8. Kalachnik, J. E., Sprague, R. L., & Slaw, K. M. (1988). Training clinical personnel to assess for tardive dyskinesia. Progress in Neuropsychopharmacology & Biological Psychiatry, 12, 749-762.
9. Kampert, A. C., & Goreczny, A. J. (2007). Community involvement and socialization among individuals with mental retardation. Research in Developmental Disabilities, 28, 278-286.
10. Kaushik, S., Lindenmayer, J. P., & Khan, A. (2007). Management of antipsychotic side effects. Primary Psychiatry, 14, 77-82.
11. LeBlanc, L. A., Geiger, K. B., Sautter, R. A., & Sidener, T. M. (2007). Using the Natural Language Paradigm (NLP) to increase vocalizations of older adults with cognitive impairments. Research in Developmental Disabilities, 28, 437-444.
12. Matson, J. L. (1995). The Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER). Baton Rouge, LA: Disability Consultants, LLC.
13. Matson, J. L., & Baglio, C. S. (1998). Administrator's manual: Matson Evaluation of Drug Side Effects (MEDS). Baton Rouge, LA: Scientific Publishers.
14. Matson, J. L., Mayville, E. A., Bielecki, J., Barnes, W. H., Bamburg, J. W., & Baglio, C. S. (1998). Reliability of the Matson Evaluation of Drug Side-Effects scale (MEDS). Research in Developmental Disabilities, 19, 501-506.
15. Matson, J. L., Mayville, E. A., Bielecki, J., Smalls, Y., & Eckholdt, C. S. (2002). Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities. Research in Developmental Disabilities, 23, 224-233.
16. Matson, J. L., & Minshawi, N. F. (2007). Functional assessment of challenging behavior: Toward a strategy for applied settings. Research in Developmental Disabilities, 28, 353-361.
17. McGillivray, J. A., & McCabe, M. P. (2007). Early detection of depression and associated risk factors in adults with mild/ moderate intellectual disability. Research in Developmental Disabilities, 28, 59-70.
18. Miller, C. H., & Fleischhacker, W. W. (2000). Managing antipsychotic-induced acute and chronic akathisia. Drug Safety, 22, 73-81.
19. Pierre, J. M. (2005). Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention, and management. Drug Safety, 28, 191-208.
20. Plant, K. M., & Sanders, M. R. (2007). Reducing problem behavior during care-giving in families of preschool-aged children with developmental disabilities. Research in Developmental Disabilities, 28, 362-387.
21. Ramirez, S. Z., & Lukenbill, J. F. (2007). Development of the fear survey for adults with mental retardation. Research in Developmental Disabilities, 28, 225-237.
22. Richardson, M. A., Haugland, G., Pass, R., & Craig, T. J. (1986). The prevalence of tardive dyskinesia in a mentally retarded population. Psychopharmacology Bulletin, 22, 243-249.
23. Rodnitzky, R. L. (2002). Drug-induced movement disorders. Clinical Neuropharmacology, 25, 142-152.
24. Sparrow, S., Balla, D., & Cicchetti, D. V. (1984). The Vineland Adaptive Behavior Scales (Survey Form). Circle Pines, MN: American Guidance Service.
25. Sprague, R. L., & Kalachnik, J. E. (1991). Reliability, validity, and a total score cutoff for the Dyskinesia Identification System: Condensed User Scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacology Bulletin, 27, 51-58.
26. Sprague, R. L., Kalachnik, J. E., & White, D. A. (1985). The Dyskinesia Identification System: Condensed User Scale (DISCUS). Champaign, IL: Institute for Child Behavior and Development, University of Illinois.
27. Swanson, J. M., Christian, D. L., Wigal, T., Clevenger, W., Cavoto, K. F., Ackerland, V., et al. (1996). Tardive dyskinesia in a developmentally disabled population: Manifestation during the initial stage of a minimal effective dose program. Experimental and Clinical Psychopharmacology, 4, 218-223.
28. Wszola, B. A., Newell, K. M., & Sprague, R. L. (2001). Risk factors for tardive dyskinesia in a large population of youths and adults. Experimental and Clinical Psychopharmacology, 9, 285-296.